best classintroduc imvexxi
quick read sidelin
analyst certif import disclosur see
back wider loss choo vs guidanc addit market higher tax rate kor beat
ep estim driven better sale first flat north america comp sinc gross margin ebit margin bp
better vs guid ep expect modest growth rest year primarili choo season
dilut think conserv given acceler momentum handbag accessori watch jewelri
neg categori retail maintain above-guid ep valuat back punit view beat rais
set-up next year
best classintroduc imvexxi
announc fda approv imvexxi estradiol vagin insert label support view best-in-class profil base
safeti efficaci conveni imvexxi approv treatment moderate-to-sever dyspareunia vagin pain associ
sexual activ symptom vulvar vagin atrophi vva due menopaus base wide accept guidelin patient begin
treatment lowest avail dose mean imvexxi becom treatment choic dyspareunia optimist
potenti imvexxi rais probabl success peak sale reiter
outperform rate rais pt highlight detail insid
quick read sidelin
share perform-r dick sport good ralli significantli today pre-market follow better-than-expect apr
result higher jan guidanc applaud manag success difficult sector backdrop exasper
unfavor weather much howev recommend client remain sidelin view meaning challeng
remain chain continu reconfigur busi model compet better increasingli omni-channel marketplac includ
outsiz price promot oper struggl propens lead vendor go direct consum shift consum
demand key categori client seek compel larger cap growth name advis look share outperform-
cloud
spoke manag appear focus build spectrum increas coverage/capac
correct rout opinion requir capital-expenditure increas estim depreci believ subscrib trend
look better easier comp vz launch unlimit year ago port ratio improv t/vz less promot
due focu fixed-wireless respect network improv decreas ep expect next
quarter due higher given focu afford devic shorter live stand-alon trade
ebitda half turn vz/t much faster growth
